ShockWave Medical, Inc. (SWAV)

NASDAQ: SWAV · IEX Real-Time Price · USD
174.33
5.66 (3.36%)
At close: May 27, 2022 4:00 PM
175.58
1.25 (0.72%)
After-hours:May 27, 2022 6:01 PM EDT

Company Description

ShockWave Medical, Inc., a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide.

The company offers M5 catheters for treating above-the-knee peripheral artery disease (PAD); C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee PAD.

It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors.

The company was incorporated in 2009 and is headquartered in Santa Clara, California.

ShockWave Medical, Inc.
CountryUnited States
IPO DateMar 7, 2019
IndustryHealth Care Equipment & Supplies
SectorHealth Care
Employees657
CEODouglas Godshall

Contact Details

Address:
5403 Betsy Ross Dr
Santa Clara, California 95054
United States
Phone510 279 4262
Websiteshockwavemedical.com

Stock Details

Ticker SymbolSWAV
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
IPO Price$17.00
CIK Code1642545

Key Executives

NamePosition
Douglas E. Godshall M.B.A.President, Chief Executive Officer and Director
Daniel Puckett MBAChief Financial Officer, Principal Financial Officer and Secretary
Isaac ZachariasChief Commercial Officer
Daniel HawkinsFounder and Senior Advisor
John M. AdamsCo-Founder and Technical Advisor
Mike MaszyVice President of Operations
Trinh PhungChief Accounting Officer, Principal Accounting Officer and Vice President of Finance
Debbie KasterVice President of Investor Relations
Hajime Tada J.D.General Counsel and Secretary
Rob Williamson Jr.Vice President of Sales

Latest SEC Filings

DateTypeTitle
May 23, 20224Statement of changes in beneficial ownership of securities
May 13, 20224Statement of changes in beneficial ownership of securities
May 12, 20224Statement of changes in beneficial ownership of securities
May 9, 202210-QQuarterly report [Sections 13 or 15(d)]
May 9, 20228-KCurrent report
Apr 29, 20224Statement of changes in beneficial ownership of securities
Apr 29, 2022DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 29, 2022DEF 14AOther definitive proxy statements
Apr 28, 20224Statement of changes in beneficial ownership of securities
Apr 21, 20224Statement of changes in beneficial ownership of securities
View All SEC Filings